Ocumetics Technology Corp. (TSXV: OTC | OTCQB: OTCFF | FRA: 2QBO) announced highly encouraging six-month postoperative results from the first group of patients in its first-in-human (FIH) clinical study of the Ocumetics Accommodating Intraocular Lens. The results demonstrate clinical outcomes that meet and exceed expectations, with all patients experiencing continuing vision improvements and a strong safety profile.
Patients in Group One entered the study with very poor vision, including one individual considered legally blind. At six months post-surgery, patients continue to show improved vision and stable visual acuity. Anecdotally, all patients reported life-changing results from the lens implantations, including the ability to read, drive, and live independently again.
“After six months, what stands out most is not just the clinical performance of the Ocumetics Lens, but the profound impact on patients’ quality of life,” said Dean Burns, President and CEO of Ocumetics. “Patients who entered this study with severely impaired vision are now reading, driving, and living independently again. We’re developing a technology that dramatically improves people’s quality of life and we couldn’t be happier.”
The company continues to leverage surgeon feedback and patient experience into ongoing product enhancements. Updated lens refinements are currently in manufacturing and testing, supporting the planned initiation of Group Two surgeries. “The measurable improvements in visual acuity and consistency we are seeing at six months give us tremendous confidence as we advance to the next phase of our clinical program,” added Burns. “We are not only validating our technology, we are demonstrating its real-world impact.”
Ocumetics will host a webinar on April 22, 2026, at 4:00 PM ET to discuss the six-month study results and important updates on the FIH study. Register at www.ocumetics.com/webinar.
The Ocumetics Lens is a dynamic intraocular lens designed to fit within the eye’s natural lens compartment, potentially eliminating the need for corrective lenses. It uses the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without perceptible time lag.
These results reinforce the expected performance of Ocumetics’ inaugural accommodating intraocular lens and build momentum toward transforming vision correction through innovation. For further information, contact Dave Burwell, Director of Investor Relations, at dave.burwell@ocumetics.com or (403) 410-7907.
